18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
Launched by M.D. ANDERSON CANCER CENTER · Aug 9, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special type of imaging scan, called an 18F-FSPG PET/CT scan, can help doctors understand how well patients with esophageal cancer are responding to their treatment, which includes chemotherapy and radiation. The goal is to see if this scan can provide useful information without needing invasive procedures, making it easier for patients and their healthcare providers to monitor treatment progress.
To participate, you must be at least 18 years old and have locally advanced esophageal cancer that has not been treated before. Specifically, your cancer should be larger than 2 cm, and you should be planning to receive a combination of chemotherapy and radiation as your main treatment. If you join the trial, you will undergo the PET/CT scan before starting treatment, and you’ll need to give written consent to participate. It's important to note that certain individuals, such as pregnant women or those with specific medical conditions, may not be eligible for this study. Overall, this trial aims to improve how we track treatment effectiveness in esophageal cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \* ≥ 18 years of age
- • Patients with locally advanced esophageal cancer
- • Patients with untreated documented carcinoma of the esophagus that is \> 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy
- • Ability to provide written informed consent in accordance with institutional policies
- • Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical
- Exclusion Criteria:
- • \* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
- • Pregnant or lactating females
- • Have an allergy to intravenous contrast
- • eGFR \< 30
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Steven H Lin, MD, PHD
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported